C ardiac hypertrophy is often accompanied by cardiac remodeling characterized by loss of cardiac myocytes, interstitial fibroblasts, and collagen deposition, leading to decreased ventricular compliance and an increased risk for heart failure. The mortality for patients with heart failure is still high, although some improvements have been demonstrated in patients with systolic heart failure. [1] [2] [3] To improve the therapeutic strategy for patients with heart failure, especially diastolic heart failure, further research and investigations to better understand the molecular and biochemical mechanism are needed.
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Serotonin (5-hydroxytryptamine ) affects many physiological functions through the interaction with specific G-coupled membrane receptors, 5-HT receptors. There are 4 classes of 5-HT receptors (5-HT 1/5 , 5-HT 2 , 5-HT 3 , and 5-HT 4/6/7 ). 4 Serotonin, via the 5-HT 2B receptor, regulates cardiac development and function. 5 Transgenic mice with a 5-HT 2B receptor gene ablation show embryonic and neonatal death caused by lack of trabeculae in the heart. 6 5-HT 2B receptors are essential for isoproterenol-induced cardiac hypertrophy, which involves the regulation of interleukin-6, interleukin-1␤, and tumor necrosis factor-␣ cytokine production by cardiac fibroblasts. 7 The 5-HT 2B receptor has been shown functionally coupled to reactive oxygen species synthesis through NAD(P)H oxidase stimulation in neuronal cells 8 and in angiotensin II and isoproterenol-induced cardiac hypertrophy. 9 Recently, 5-HT 2B receptor blockade has been shown to prevent the cardiac hypertrophy induced by angiotensin II or isoproterenol infusion. 9 The 5-HT 2B receptor has also been shown to be involved in cardiac hypertrophy by acting directly on cardiac myocytes. 10 Serotonin plasma level and serotonin activity are increased in patients with heart failure and in animal studies with cardiac hypertrophy induced by aortic constriction. 11 These findings may indicate that serotonin induces cardiac hypertrophy or heart failure through the 5-HT 2B receptor.
Most of the previous studies on cardiac hypertrophy focus on the molecular and biochemical mechanisms, including neuroendocrine activation, signaling pathways, and even therapeutic strategy in cardiac myocytes. 12, 13 In this issue of Circulation Research, Jaffré et al 14 report novel findings regarding the regulatory mechanisms of the 5-HT 2B receptor and local angiotensin II in cardiac fibroblasts. These regulatory mechanisms are required for isoproterenol-dependent cardiac hypertrophy in mice. Expression of 5HT 2B receptors in cardiac fibroblasts is required for isoproterenol-induced cardiac hypertrophy. 5HT 2B receptors, angiotensin II and angiotensin II type 1 (AT 1 ) receptors are necessary intermediates for isoproterenol-induced cytokine release in adult cardiac fibroblasts. They found a common signal transduction pathway for 5-HT 2B receptor-and AT 1 receptor-induced cytokine production that requires the transactivation of the epidermal growth factor /ErbB-receptor family via matrix metalloproteinase (MMP)-dependent cleavage of heparinbinding epidermal growth factor. This is an interesting study to address the role of cardiac fibroblasts on adrenergic dependent cytokine production and cardiac hypertrophy through serotonin/angiotensin II. In particular, the generation of mice overexpressing the 5-HT 2B receptor only in cardiac myocytes through mating ␣-MHC-5-HT 2B ϩ/Ϫ and 5-HT 2B
Ϫ/Ϫ is a very good way to demonstrate the importance of noncardiac 5-HT 2B receptor. These findings may have important clinical implications because sympathetic activity, 5-HT 2B receptor expression, and plasma cytokines were all increased in patients with heart failure. These data clearly indicate that the 5-HT 2B receptor in cardiac fibroblasts may represent a new therapeutic target to reduce cardiac pathological hypertrophy and hypertrophy-induced heart failure.
The etiology of cardiac hypertrophy is complex, including mechanical stress, several neurohumoral factors (angiotensin II, endothelin, and ␤-adrenergic agonist, etc). Although Jaffré and colleagues 9, 14 have demonstrated that a 5-HT 2B receptor antagonist could prevent cardiac hypertrophy by isoproterenol or angiotensin II infusion, the effect of a 5-HT 2B receptor antagonist on other models of cardiac hypertrophy is not known. The authors used coimmunolocalization and pulldown assay to prove that the AT 1 receptor and 5-HT 2B receptor form a heterodimeric complex. However, it is still not known whether antagonists of the AT 1 receptor, an effective agent to improve systolic heart failure, have the same effect as 5-HT 2B receptor antagonists to prevent cardiac hypertrophy. It is also not known whether there is a synergistic effect of combination of 5-HT 2B receptor and AT 1 receptor antagonists to treat hypertrophy-induced heart failure.
Different classes and subtypes of 5-HT receptors may work differently in cardiac myocytes. Jaffré et al did not investigate the role of other 5-HT receptors in their transgenic mice model. Recently, Qvigstad et al 15 have reported that rats with acute heart failure develop ventricular inotropic responsiveness to serotonin, mediated through G q -coupled 5-HT 2A receptors and G s -coupled 5-HT 4 receptors. In chronic heart failure, serotonin increases ventricular inotropic response through 5-HT 4 receptor. 16 5-HT 4 receptor blockers reduce cardiac energy consumption in chronic heart failure. Using 5-HT 2B receptor antagonists may counteractively increase serotonin level, which may increase binding to other 5-HT receptors and induce adverse cardiac effects (Figure) . The 5-HT 2B receptor increases oxidative stress in cardiac fibroblasts and 5-HT 2B receptor blockade reduces the oxidative stress. 9 However, recent studies demonstrated that serotonin stimulates cardiac myocyte hypertrophy by receptor independent and receptor-dependent mechanism 15 and that serotonin induces cardiac myocytes apoptosis is receptorindependent. 17 It has not been reported whether the elevated serotonin by 5-HT 2B receptor blockade could have deleterious or neutral effect on cardiac myocytes.
MMPs, which are important markers for cardiac fibrosis in patients with diastolic heart failure, 18 are involved in the downstream signaling of the adrenergic-dependent cardiac hypertrophy reported by Jaffré et al. 14 Active fibrotic process that produces increased ventricular stiffness compromising filling may explain the pathophysiology of diastolic heart failure. A primary cause of diastolic heart failure is hypertensive heart disease, which causes cardiac hypertrophy and functional abnormalities. Although MMP inhibitors prevent angiotensin II-and serotonin-induced cytokine release by cardiac fibroblasts, it is not known whether 5-HT 2B receptor blockade can reduce MMP content or activity in the cardiac fibroblasts.
In summary, Jaffré et al 14 clearly demonstrated the requirement of angiotensin II and autocrine stimulation of AT 1 receptors interacting with 5-HT 2B receptors in cardiac fibroblasts for ␤-adrenergicdependent hypertrophic responses. A new target for treatment of heart failure may give new hope for improving prognosis and prolong survival of patients with heart failure. The findings reported by Jaffré et al provide the evidence that the 5-HT 2B receptor may represent a new therapeutic target to reduce cardiac hypertrophy and hypertrophy-induced heart failure. If the safety and efficacy of a 5-HT 2B receptor antagonist to treat cardiac hypertrophy or hypertrophy-induced heart failure can be confirmed in larger animal studies, application of this kind of therapy to human study may be warranted.
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